Tbc1d22a, which encodes a putative Rab33 GTPase-activating protein, is involved in multiple biological aspects. It has been associated with pathways related to Golgi organization as it interacts with ACBD3, and the interaction between them can be influenced by viral proteins, suggesting its role in processes related to viral replication [3].

In ovarian cancer, Tbc1d22a has emerged as a significant gene. High expression of Tbc1d22a is related to poor prognosis in ovarian serous cystadenocarcinoma, and it was identified as a poor prognostic gene of cisplatin-resistant ovarian cancer. Its overexpression increases the IC50 for cisplatin and paclitaxel, indicating its potential role in drug resistance. Also, it is positively correlated with M2 macrophage infiltration and the expression of most immune checkpoint genes [1,2]. Additionally, in individuals with Phelan-McDermid syndrome, a 3 Mb genomic region on 22q13.31 containing Tbc1d22a was found to be significantly associated with seizure prevalence [4].

In conclusion, Tbc1d22a plays crucial roles in various biological processes and disease conditions. In ovarian cancer, it is closely linked to prognosis and drug resistance, and in Phelan-McDermid syndrome, it may be associated with seizure phenotypes. Understanding the function of Tbc1d22a provides insights into the mechanisms of these diseases, potentially guiding the development of new therapeutic strategies.